Yanhong Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yanhong Ren has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Rutong Yu
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China
2 shared publications Duo Xu
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People’s Republic of China
1 shared publicationHan Yang
Department of Neurology, The First Hospital of Changsha, Changsha, 410008, People’s Republic of China
1 shared publication- Jianchang Xu
Department of Neurosurgery, The Affiliated Huai'an Hospital of Xuzhou Medical University, South Huai-Hai Road 62, Huai'an, Jiangsu, China
1 shared publication - Shangfeng Gao
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, China
1 shared publication Zhengkui Zhang
Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 625-638
Application of Multifunctional Metal Nanoparticles in the Treatment of Glioma
Glioma is the most common primary malignant brain tumor with a poor survival rate. It is characterized by diffuse and invasive growth and heterogeneity, which limits tumor identification and complete resection. Therefore, the precise detection and postoperative adjuvant therapy of gliomas have become increasingly important and urgent. Nanotechnology, with its excellent biocompatibility and controllable chemical properties, has attracted much attention in recent decades. Metal nanoparticles are widely used in the field of biomedical imaging and detection, and have shown promising applications in targeted drug delivery and therapy. The current review aims to systematically summarize the application of different types of metal nanoparticles in the treatment and detection of glioma. We also discussed the advantages and mechanisms of metal nanoparticles when used for glioma therapy, including chemotherapy, radiotherapy and photothermal therapy. We hope to promote the application of metallic nanoparticles in glioma diagnosis and treatment, moving towards clinical translation to benefit patients.
- 1 January 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 625-638
Open AccessApplication of Multifunctional Metal Nanoparticles in the Treatment of Glioma
Glioma is the most common primary malignant brain tumor with a poor survival rate. It is characterized by diffuse and invasive growth and heterogeneity, which limits tumor identification and complete resection. Therefore, the precise detection and postoperative adjuvant therapy of gliomas have become increasingly important and urgent. Nanotechnology, with its excellent biocompatibility and controllable chemical properties, has attracted much attention in recent decades. Metal nanoparticles are widely used in the field of biomedical imaging and detection, and have shown promising applications in targeted drug delivery and therapy. The current review aims to systematically summarize the application of different types of metal nanoparticles in the treatment and detection of glioma. We also discussed the advantages and mechanisms of metal nanoparticles when used for glioma therapy, including chemotherapy, radiotherapy and photothermal therapy. We hope to promote the application of metallic nanoparticles in glioma diagnosis and treatment, moving towards clinical translation to benefit patients.
- Open Access
- 1 January 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024 (1) , 6147483
ITGA1 Promotes Glioma Cell Proliferation and Affects Immune Cell Infiltration in Low‐Grade Glioma
Background: Low‐grade glioma (LGG) is a commonly occurring type of central nervous system cancer. Integrin α1 (ITGA1), a family member of integrins, is implied in the malignant development of cancers, but the fundamental role of ITGA1 has not been illustrated yet in glioma. This study aimed to evaluate the prognostic value of ITGA1.Methods: Correlations between ITGA1 and relevant clinical features were analyzed in the LGG datasets based on Chinese Glioma Genome Atlas (CGGA) and Tumor Genome Atlas (TCGA). Glioma clinical samples and glioma cell lines were identified at the level of mRNA and protein level by Western blot. Cox regression were developed to assess the involvement of ITGA1 expression in predicting survival in LGG patients. Application of GSEA enrichment analysis to reveal ITGA1‐mediated biological functions in LGG. Using TIMER 2.0 to analyze correlations between immune cell infiltration. In addition, ITGA1 high expression was analyzed for correlation with immune checkpoint‐related genes and cumulative survival time.Results: ITGA1 was significantly more expressed in LGG than in normal samples. Cox regression indicated that ITGA1 was a risk factor independently for prognosis in LGG patients. GSEA enrichment analysis indicated that ITGA1 was engaged in several immunomodulatory processes. ITGA1 expression was shown to be highly correlated with the immune score, stromal score, and estimate score in LGG. ITGA1 was significantly related to the immune checkpoint‐associated gene expression. In vivo experiments showed that overexpression of ITGA1 promoted glioma cell invasion.Conclusion: High ITGA1 expression is correlated with immune infiltration of the low‐grade tumor, leading to poor prognoses in LGG patients.
- 1 January 2024
- Published by Wiley in Mediators of Inflammation
- Vol. 2024 (1) , 6147483
Open AccessITGA1 Promotes Glioma Cell Proliferation and Affects Immune Cell Infiltration in Low‐Grade Glioma
Background: Low‐grade glioma (LGG) is a commonly occurring type of central nervous system cancer. Integrin α1 (ITGA1), a family member of integrins, is implied in the malignant development of cancers, but the fundamental role of ITGA1 has not been illustrated yet in glioma. This study aimed to evaluate the prognostic value of ITGA1.Methods: Correlations between ITGA1 and relevant clinical features were analyzed in the LGG datasets based on Chinese Glioma Genome Atlas (CGGA) and Tumor Genome Atlas (TCGA). Glioma clinical samples and glioma cell lines were identified at the level of mRNA and protein level by Western blot. Cox regression were developed to assess the involvement of ITGA1 expression in predicting survival in LGG patients. Application of GSEA enrichment analysis to reveal ITGA1‐mediated biological functions in LGG. Using TIMER 2.0 to analyze correlations between immune cell infiltration. In addition, ITGA1 high expression was analyzed for correlation with immune checkpoint‐related genes and cumulative survival time.Results: ITGA1 was significantly more expressed in LGG than in normal samples. Cox regression indicated that ITGA1 was a risk factor independently for prognosis in LGG patients. GSEA enrichment analysis indicated that ITGA1 was engaged in several immunomodulatory processes. ITGA1 expression was shown to be highly correlated with the immune score, stromal score, and estimate score in LGG. ITGA1 was significantly related to the immune checkpoint‐associated gene expression. In vivo experiments showed that overexpression of ITGA1 promoted glioma cell invasion.Conclusion: High ITGA1 expression is correlated with immune infiltration of the low‐grade tumor, leading to poor prognoses in LGG patients.